Peptide-Oligonucleotide Nanohybrids Designed for Precise Gene Therapy of Rheumatoid Arthritis

Area of Science:

• Biomedical Engineering
• Gene Therapy
• Nanotechnology

Background:

• Rheumatoid arthritis (RA) is a complex autoimmune disease causing inflammation, bone resorption, and osteoporosis, with limited effective treatments.
• Current oligonucleotide (ON) gene therapy for RA faces challenges like enzymatic degradation, poor targeting, cell penetration, and endolysosomal escape.

Purpose of the Study:

• To develop novel peptide and oligonucleotide (PON) nanohybrids for enhanced RA treatment.
• To overcome the limitations of traditional ON delivery systems for RA therapy.

Main Methods:

• Fabrication of engineered peptide and oligonucleotide (PON) nanohybrids.
• Evaluation of nanohybrid properties including biosafety, targeting, cell penetration, ROS scavenging, and endolysosomal escape.
• Assessment of in vitro suppression of inflammatory responses and osteoclastogenesis.
• In vivo studies in RA models to evaluate therapeutic effects on bone destruction and osteoporosis.

Main Results:

• PON nanohybrids demonstrated good biosafety and targeted delivery to inflammatory regions.
• Nanohybrids facilitated cell membrane penetration and endolysosomal escape.
• PON nanohybrids effectively suppressed inflammatory responses and osteoclastogenesis in macrophages.
• In vivo administration ameliorated joint bone destruction and systemic osteoporosis, showing prophylactic effects against RA progression.

Conclusions:

• The study presents a novel PON nanohybrid strategy for precise RA treatment.
• This approach broadens the biomedical applications of gene therapy delivery systems for autoimmune diseases.